In focus · trending topic

#IMUN

31 stories · following the connections

Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017

By Nasdaq OMXMay 31, 2017, 1:33 PM UTC

Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017

By Nasdaq OMXMay 31, 2017, 1:33 PM UTC

CORRECTING and REPLACING: Immune Therapeutics, Inc.

By Nasdaq OMXMay 22, 2017, 1:25 PM UTC

CORRECTING and REPLACING: Immune Therapeutics, Inc.

By Nasdaq OMXMay 22, 2017, 1:25 PM UTC

Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria

By Nasdaq OMXMay 22, 2017, 12:42 PM UTC

Immune Therapeutics, Inc. Files Lodonal New Drug Application in Kenya

By Nasdaq OMXApr 25, 2017, 3:37 PM UTC

Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya

By Nasdaq OMXApr 17, 2017, 3:45 PM UTC

Immune Therapeutics, Inc. Strengthens Balance Sheet With Debt Settlement

By Nasdaq OMXApr 12, 2017, 5:36 PM UTC